Latest Breaking News On - Jielun zhu - Page 4 : comparemela.com

I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.

United statesHong kongEmilie wuDeepa goturJoan shenGigi fengJielun zhuExchange commissionPrnewswire the company nasdaqPiacente group incLymphocyte ratioPrivate securities litigation reform actChief financialChief communicationsPiacente groupI mab

I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer s Disease

I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer s Disease
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongEmilie wuJiangsu nhwaGigi fengJingwu zangJielun zhuPrnewswire the company nasdaqDrug administrationPiacente group incExchange commissionInvestigational new drugGreater chinaChief financialChief communicationsPiacente group

I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China

I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongSouth koreaEmilie wuJoan shenGigi fengJielun zhuPrnewswire the company nasdaqPiacente group incExchange commissionChina national medical products administrationDrug evaluationPrivate securities litigation reform actChief financialChief communicationsPiacente group

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongSan diegoZihao wangEmilie wuGigi fengTaylor guoJielun zhuExchange commissionPrnewswire the company nasdaqPiacente group incChief scientific officerChang chenSequoia capital chinaVision plus capitalVertex ventures

I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio

I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongSan diegoEmilie wuJoan shenGigi fengJielun zhuPrnewswire the company nasdaqBio incPiacente group incExchange commissionPrivate securities litigation reform actChief financial officerChief communications officerPiacente groupஒன்றுபட்டது மாநிலங்களில்